老年房颤患者口服抗凝药物的治疗进展

Treatment progress of oral anticoagulants in elderly patients with atrial fibrillation

ES评分 0

DOI 10.12208/j. ijim.20220072
刊名
International Journal of Internal Medicine
年,卷(期) 2022, 3(3)
作者
作者单位

芜湖市第二人民医院 安徽芜湖 ;

摘要
房颤(心房颤动)具有高病发率和高死亡率特点,随着我国人口老龄化不断推进,老年患者房颤形势不容乐观。目前,抗凝治疗已被国内外房颤指南推荐为防治房颤患者卒中的核心策略。近年来,随着抗凝药物不断更新与应用,老年房颤患者的抗凝药物治疗取得了重大进展,本文就传统与新型抗凝药物在房颤中的疗效及应用进行归纳总结,以期为老年房颤患者的抗凝药物工作提供一定指导。
Abstract
Atrial fibrillation (AF) has the characteristics of high morbidity and mortality. With the conti- nuous advancement of population aging in China, the situation of elderly patients with AF is not optimistic. At present, anticoagulation therapy has been recommended as the core strategy to prevent stroke in patients with atrial fibrillation by domestic and foreign atrial fibrillation guidelines. In recent years, with the continuous updating and application of anticoagulant drugs, the treatment of elderly patients with atrial fibrillation has made significant progress. This paper summarizes the efficacy and application of traditional and new anticoagulant drugs in atrial fibrillation, in order to provide some guidance for the work of anticoagulant drugs in elderly patients with atrial fibrillation.
关键词
房颤;老年患者;抗凝药;华法林;达比加群酯;利伐沙班;阿哌沙班;依度沙班
KeyWord
Atrial fibrillation; Elderly patients; Anticoagulants; Warfarin; Dabigatran ester; Rivaroxaban; Apixaban; Idusaban
基金项目
页码 16-19
  • 参考文献
  • 相关文献
  • 引用本文

樊娟*. 老年房颤患者口服抗凝药物的治疗进展 [J]. 国际内科前沿杂志. 2022; 3; (3). 16 - 19.

  • 文献评论

相关学者

相关机构